<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695331</url>
  </required_header>
  <id_info>
    <org_study_id>CMUBH R96007</org_study_id>
    <secondary_id>DMR96-IRB-176</secondary_id>
    <nct_id>NCT00695331</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Titrated Oral Misoprostol Solution for Labor Augmentation</brief_title>
  <official_title>A Comparison of Titrated Oral Misoprostol Solution to Intravenous Oxytocin for Labor Augmentation: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of titrated oral misoprostol
      solution with intravenous oxytocin for labor augmentation in women without adequate uterine
      contractions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous labor course necessitate augmentation when uterine contractions are inadequate. When
      the cervix is favorable, labor augmentation attempts are more likely to be successful.
      Augmentation is these women is traditionally undertaken with intravenous oxytocin and
      amniotomy, either alone or in combination.

      In our previous trial, it has been proven that the method of titrated oral misoprostol is
      associated with a lower incidence of uterine hyperstimulation and a lower cesarean delivery
      rate than vaginal misoprostol for labor induction in patients with unfavorable cervix.
      Because administering Misoprostol solution is easy and cost saving, it is worth to develop
      this novel method in labor augmentation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of women delivering infants vaginally within 12 hours of augmentation</measure>
    <time_frame>post vaginal delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>uterine hyperstimulation rate</measure>
    <time_frame>post vaginal delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Labor</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titrated Oral Misoprostol Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Oxytocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Titrated Misoprostol Solution</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Titrated Intravenous Oxytocin</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Piton-S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnancy between 36 and 42 weeks of gestation

          -  Live singleton

          -  Cephalic presentation

          -  A reassuring fetal heart rate pattern

          -  Bishop score greater than 6

          -  Inadequate uterine contraction (less than or equal to 2 per 10 minutes)

        Exclusion Criteria:

          -  Nonreassuring fetal heart rate pattern

          -  Parity more than five

          -  Uterine scar

          -  Suspected placental abruption with abnormal fetal heart rate

          -  Vaginal bleeding other than &quot;bloody show&quot;

          -  Significant maternal cardiac, renal, or hepatic disease

          -  hypersensitivity to oxytocin, misoprostol or prostaglandin analogues
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi-Yann Cheng, MD</last_name>
    <role>Study Chair</role>
    <affiliation>China Medical University Beigang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Ho, MD</last_name>
    <phone>886-4-22062121</phone>
    <phone_ext>4132</phone_ext>
    <email>mi.ho@msa.hinet.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shi-Yann Cheng, MD</last_name>
    <phone>886-5-7837901</phone>
    <phone_ext>1502</phone_ext>
    <email>shiyann@ms18.url.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Labor Unit, Department of Obstetric and Gynecology, China Medical Univertiy Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Ho, MD</last_name>
      <phone>886-4-22062121</phone>
      <phone_ext>4132</phone_ext>
      <email>mi.ho@msa.hinet.net</email>
    </contact>
    <contact_backup>
      <last_name>Shi-Yann Cheng, MD</last_name>
      <phone>886-5-7837901</phone>
      <phone_ext>1502</phone_ext>
      <email>shiyann@ms18.url.com.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Ming Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.cmuh.org.tw</url>
    <description>China Medical University Hospital</description>
  </link>
  <reference>
    <citation>Cheng SY, Ming H, Lee JC. Titrated oral compared with vaginal misoprostol for labor induction: a randomized controlled trial. Obstet Gynecol. 2008 Jan;111(1):119-25. doi: 10.1097/01.AOG.0000297313.68644.71.</citation>
    <PMID>18165400</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2008</study_first_submitted>
  <study_first_submitted_qc>June 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>July 8, 2008</last_update_submitted>
  <last_update_submitted_qc>July 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Shi-Yann Cheng</name_title>
    <organization>China Medical University Beigang Hospital</organization>
  </responsible_party>
  <keyword>Labor Augmentation</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Oxytocin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

